05:59 AM EDT, 09/17/2025 (MT Newswires) -- GSK (GSK) said Wednesday it plans to invest $30 billion in the US over the next five years to expand research and development and strengthen its supply chain infrastructure.

The company said its plan includes a $1.2 billion investment in advanced biopharma manufacturing and lab facilities, as well as expanding AI and digital technologies across its US operations.

As part of the investment, GSK said it will construct a new biologics flex factory in Upper Merion, Pennsylvania, starting in 2026, to support the development of potential treatments for respiratory diseases and cancer.

The company also said that additional funding will be directed toward upgrading manufacturing sites in four states, adding new drug substance capabilities, and enhancing device and auto-injector production.

The company said the investments are expected to create hundreds of skilled jobs and support its existing 15,000-person US workforce.